Centessa Pharmaceuticals plc (NASDAQ:CNTA) Sees Large Increase in Short Interest

Centessa Pharmaceuticals plc (NASDAQ:CNTA) saw a large increase in short interest in July. As of July 15th, there was short interest totalling 1,450,000 shares, an increase of 27.2% from the June 30th total of 1,140,000 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average trading volume of 246,600 shares, the days-to-cover ratio is currently 5.9 days.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock traded up $0.07 during mid-day trading on Tuesday, hitting $10.72. The company’s stock had a trading volume of 1,352 shares, compared to its average volume of 306,212. The company’s fifty day simple moving average is $9.14 and its 200-day simple moving average is $9.61. Centessa Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $12.45. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.37 and a current ratio of 10.37.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Monday, May 13th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.03. On average, equities research analysts forecast that Centessa Pharmaceuticals will post -1.62 earnings per share for the current year.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CNTA. Quarry LP bought a new stake in Centessa Pharmaceuticals in the 4th quarter valued at about $48,000. China Universal Asset Management Co. Ltd. increased its holdings in Centessa Pharmaceuticals by 371.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock worth $51,000 after purchasing an additional 5,037 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Centessa Pharmaceuticals during the 1st quarter worth approximately $109,000. Jump Financial LLC bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. Finally, Trexquant Investment LP bought a new stake in Centessa Pharmaceuticals during the 4th quarter worth approximately $114,000. 82.01% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on CNTA shares. Oppenheimer started coverage on Centessa Pharmaceuticals in a report on Thursday, July 18th. They set an “outperform” rating and a $14.00 price objective on the stock. Morgan Stanley lifted their target price on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a report on Friday, June 21st. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $15.00 target price on shares of Centessa Pharmaceuticals in a report on Monday, April 1st. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.